View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Aalberts: highlights ING Benelux Conference Brussels 2024, Ackermans & Van Haaren: Highlights ING Benelux Conference Brussels,Ackermans & Van Haaren: Strong operational performance of underlying companies and guidance fine-tuned upwards, AMG: Highlights ING Benelux Conference Brussels, Aperam: Highlights ING Benelux Conference Brussels, Arcadis: Highlights ING Benelux conference, Azelis: Highlights ING Benelux Conference Brussels, Bekaert: Guidance cut and €200m buyback as sweetener, CFE: No new...

X-Fab Silicon Foundries SE: 1 director

A director at X-Fab Silicon Foundries SE bought 185,548 shares at 4.450EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ABN AMRO: 3Q strong as expected, SBB decision moved out to 1H25. IMCD: Successful ABB. Just Eat Takeaway.com: So long, GrubHub. Universal Music Group: Spotify 3Q24 results guidance beat on margins and subscribers

Jacob Mekhael ... (+5)
  • Jacob Mekhael
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Lewi
 PRESS RELEASE

IMCD N.V. successfully raises EUR 300 million through an accelerated b...

IMCD N.V. successfully raises EUR 300 million through an accelerated bookbuild offering of new shares NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM AN OFFER OF SECURITIES IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION.PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.ROTTERDAM, The Netherland...

 PRESS RELEASE

IMCD N.V. LAUNCHES A CAPITAL RAISE OF EUR 300 MILLION TO INCREASE FINA...

IMCD N.V. LAUNCHES A CAPITAL RAISE OF EUR 300 MILLION TO INCREASE FINANCIAL FLEXIBILITY NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM AN OFFER OF SECURITIES IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION.PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. ROTTERDAM, The Netherlands (12 Novembe...

Stefano Toffano ... (+2)
  • Stefano Toffano
  • Wim Gille

Bpost : A very busy quarter (despite being relatively small)

>New reporting structure and integration of Staci - Bpost continues to experience pressures from all the volatility at the company as well as weakish end-market (mainly North America). Group operating income (i.c. revenue) for the quarter came in at € 1,025m, +4.7% yoy and -2% vs ccs and AAOBe. Adjusted EBIT came in at € 10m, in line with css. Bpost’s results were mainly driven by the new International 3PL division which now includes Staci. Pressure remains from the c...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Aperam: 3Q24 results solid, reassuring 4Q24 guidance. bpost: 3Q24 results and FY24 outlook in line. Eurocommercial Properties: Solid results, guidance confirmed at the top of the range. Euronext: A €300m buyback is next. IMCD: In line 3Q24. SBM Offshore: Prosperity taken out. Sif Group: Line 2 now also reporting for duty

Stefano Toffano
  • Stefano Toffano

IMCD GROUP : Organic growth solidly back into the positive (on easy co...

>Steady recovery of organic growth - IMCD reported operating results that were in line with ccs and our estimates. Q3 24 group revenues came in at € 1,199m, +10% yoy and +1% vs ccs. M&A continued to play an important role (+7% yoy impact on revenues in Q3 24). Importantly, group organic growth accelerated to +5% yoy during the quarter (marginally positive in Q2 24 on AAOBe). Gross margins remain relatively resilient, at 25.2% in Q3 24, up from 25.0% in Q3 23. IMCD’s Q...

Hilde Van Boxstael ... (+6)
  • Hilde Van Boxstael
  • Michiel Declercq
  • Sharad Kumar S.P
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Lewi
 PRESS RELEASE

IMCD reports EBITA of EUR 403 million in the first nine months of 2024

IMCD reports EBITA of EUR 403 million in the first nine months of 2024 Rotterdam, The Netherlands (8 November 2024) - IMCD N.V. (“IMCD” or “Company”), a global leading distribution partner, and formulator of speciality chemicals and ingredients, today announces its first nine months 2024 results.HIGHLIGHTS• Gross profit increase of 6% to EUR 909 million (+8% on a constant currency basis)• Operating EBITA increase of 1% to EUR 403 million (+3% on a constant currency basis)• Free cash flow of EUR 299 million (first nine months of 2023: EUR 364 million)• Cash earnings of EUR 4.67 (first nine m...

Guy Sips ... (+11)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Michiel Declercq
  • Sharad Kumar S.P
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update November 2024 – Adding Azelis – Removing ...

With 2 changes in our Dynamic Top Pick list (we add Azelis and we remove Solvay) we maintain a defensive stance on the market for 2H24. The long anticipated interest rate cuts by central banks have finally started. The Trump election victory in the US does not bode well for European stocks as he favours a protectionist course. Although industrial companies with a US base could actually benefit. Cleantech names with exposure to the US could also suffer (unless owned by E.Musk). We expect the US ...

Jacob Mekhael
  • Jacob Mekhael

ASH abstracts Autolus, Galapagos, MaaT

The abstracts for presentations at ASH (7-10 December) became available yesterday during the day (here). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (digging deeper into the obe-cel dataset), Galapagos (more CAR-T data and pre-clinical data on TCR-T) and MaaT (early access program in aGvHD):

 PRESS RELEASE

Galapagos to Present Results of Pioneering Innovation in Cancer Cell T...

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024 New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with poor prognoses. Our innovative decentralized cell therapy manufacturing platform delivers fresh, fit cells within a median vein-to-vein time of seven days, with potentially encouraging patient outcomes. Three abstracts, including one oral presentation for GLPG5101 in relapsed/refractory non-Hodgkin lymphoma, and a company showcase, will spotlight our cutting-e...

 PRESS RELEASE

Galapagos presenteert resultaten van baanbrekende innovatie in kankerc...

Galapagos presenteert resultaten van baanbrekende innovatie in kankerceltherapie op ASH 2024 Nieuwe fase 1/2 resultaten ondersteunen het potentieel van onze CAR T-celtherapiekandidaten, GLPG5101 en GLPG5201, om tegemoet te komen aan de onvervulde behoeften bij patiënten met een slechte prognose. Ons innovatieve gedecentraliseerde celtherapieproductieplatform levert verse, fitte cellen binnen een mediane vein-to-vein tijd van zeven dagen, met een bemoedigende impact op de resultaten voor patiënten. Drie abstracts, waaronder een mondelinge presentatie voor GLPG5101 bij recidief/refractair non...

Jacob Mekhael
  • Jacob Mekhael

Galapagos 9M24 conference call feedback

Galapagos hosted a conference call to discuss its 9M24 results. Most noteworthy is that we learned of an R&D day panned for 2025, as well as the deal structure with the company's CAR-T manufacturing partners in the US. We summarise the main takeaways below.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch